title: Can we target the α2-macroglobulin-hepcidin interaction to treat pathologic hypoferremia?
authors.affiliation: Department of Pathology & Bosch Institute, Molecular Pharmacology & Pathology Program, Blackburn Building, University of Sydney, Sydney, New South Wales, 2006, Australia.
authors.forename: Darius
authors.initials: D
authors.lastname: Lane
authors.forename: Des R
authors.initials: DR
authors.lastname: Richardson
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000473:pathology; D000890:Anti-Infective Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D064451:Hepcidins / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D057786:Peptidomimetics; D011485:Protein Binding; D000511:alpha-Macroglobulins / Q000737:chemistry / Q000378:metabolism*
chemical_list: D000890:Anti-Infective Agents; D064451:Hepcidins; D057786:Peptidomimetics; D000511:alpha-Macroglobulins